CD BioGlyco has professional glycomedicine development teams with multiple world-leading technologies to help customers comprehensively promote the development of glycomimetic-based glycomedicine.
Glycomimetic is a term used to refer to molecules that have structures similar to carbohydrates, but with some variation. This will normally result in modified biological properties. Often, modification of the structure will take place around the glycosidic linkage. Replacement of one or other of the glycosidic oxygen atoms by carbon, sulfur, nitrogen, etc. will alter the properties of the glycosidic bond. The molecules produced in this way would be called carbasugars or C-glycosides, thiosugars or thioglycosides, or iminosugars or glycosylamines. When nitrogen is introduced, the glycomimetic may become positively charged at physiological pH, meaning that it may act as an enzyme inhibitor, either by Coulombic interaction with carboxylate amino acid side-chains in the enzyme active site, or by mimicking positive-charge build-up at the transition state of the reaction, or both. Altering the structure of carbohydrates will normally result in several changes to the properties of the molecule. As well as changing the stability of the glycosidic bond, the ring-conformation may be affected. Also, the conformation of the glycosidic bond may be affected. Glycomimetics will not only help scientists in spreading light on the complex and multifarious physiological roles of carbohydrates but also in finding carbohydrate-based new drugs.
Fig.1 Glycomimetics and diversity-oriented synthesis approaches used to prepare glycomimetic libraries. (Meanwell, et al., 2021)
CD BioGlyco has developed a highly specialized carbohydrate-based glycomedicine development platform and various systematic solutions for the development of glycomimetic-based glycomedicine. CD BioGlyco provides development services of glycomimetics-based glycomedicine with pharmacophores, which are preorganized in their bioactive conformation and has improved absorption, distribution, metabolism, and excretion. Moreover, we offer high-quality diversity-oriented synthesis of glycomimetics.
CD BioGlyco has comprehensive glycomedicine development platforms to help with customers' in-depth study of glycomimetic-based glycomedicine development. Our professional research teams provide customers with the development of glycomedicine according to their needs.
If you are interested in our services, please contact us to obtain more information.
Reference:
